Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

ClinicalTrials.gov ID: NCT05517447

Public ClinicalTrials.gov record NCT05517447. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.

Study identification

NCT ID
NCT05517447
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Immunovant Sciences GmbH
Industry
Enrollment
109 participants

Conditions and interventions

Interventions

Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 6, 2022 (Actual)
Primary completion
Apr 2, 2026 (Actual)
Completion
Apr 2, 2026 (Actual)
Last update posted
Apr 29, 2026

2022 – 2026

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
Site Number - 1520 Glendora California 91741 —
Site Number - 1501 Aurora Colorado 80045 —
Site Number - 1526 Livonia Michigan 48152 —
Site Number - 1513 Rochester Minnesota 55905 —
Site Number - 1540 Las Vegas Nevada 89184 —
Site Number - 1508 Houston Texas 77030 —
Site Number - 1558 Mesquite Texas 75149 —
Site Number - 1511 Morgantown West Virginia 26506 —
Site Number - 1518 Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05517447, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 29, 2026 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05517447 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →